Irbesartan/propagermanium - Dimerix Bioscience

Drug Profile

Irbesartan/propagermanium - Dimerix Bioscience

Alternative Names: DMX-200

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dimerix Bioscience
  • Class Biphenyl compounds; Organometallic compounds; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal failure

Most Recent Events

  • 15 May 2018 Dimerix Bioscience plans a phase II trial for Focal segmental glomerulosclerosis (Adjunctive treatment) in Australia in July 2018 (ACTRN12618000910202p)
  • 15 May 2018 Dimerix plans a phase II trial for Kidney disease (Diabetic kidney disease) in Australia in the third quarter of 2018 (ACTRN12618000982213p)
  • 30 Jan 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top